November 29, 2025 a 12:38 pm
MRNA: Analysts Ratings - Moderna, Inc.
Analyst sentiment for Moderna, Inc. (MRNA) shows a complex landscape with varied perspectives. While the company continues to innovate in mRNA therapeutics, the analyst ratings suggest a cautious outlook, reflecting uncertainties in the broader market environment. Monitoring shifts in analyst ratings offers valuable insight into potential market movements.
Historical Stock Grades
| Category | Number | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 4 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 3 |
Sentiment Development
The analyst sentiment for Moderna has shifted notably over recent months, reflecting a trend towards increased caution. Key observations include:
- A clear rise in 'Hold' ratings, suggesting analysts are taking a more neutral stance.
- Stability in 'Sell' and 'Strong Sell' ratings, indicating no increased pessimism.
- A slight decline in 'Buy' categories, showing reduced confidence in aggressive upside potential.
Percentage Trends
Over the months, there was a significant realignment in analyst ratings for Moderna. In particular:
- The proportion of 'Hold' ratings increased, reaching nearly 50% of all ratings, highlighting a wait-and-see approach.
- 'Strong Buy' ratings experienced a decline, reflecting decreased aggressive bullish sentiment.
- Overall, there is a trend towards conservatism with fewer new 'Buy' entries.
- The most marked changes occurred between February 2025 and November 2025, with a visible transition to neutral stances.
Latest Analyst Recommendations
The latest analyst recommendations portray a consistent stance, with no major shifts in ratings. This consistency might suggest a firm understanding of Moderna's market position:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-21 | Underperform | Underperform | Leerink Partners |
| 2025-11-21 | Sector Perform | Sector Perform | RBC Capital |
| 2025-11-21 | Overweight | Overweight | Piper Sandler |
| 2025-11-10 | Underperform | Underperform | B of A Securities |
| 2025-11-07 | Equal Weight | Equal Weight | Barclays |
Analyst Recommendations with Change of Opinion
Analysts have occasionally shifted their opinions on Moderna, signifying reassessment amidst evolving market conditions. Recent changes include:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-02-18 | Equal Weight | Overweight | Barclays |
| 2024-12-18 | Hold | Buy | Argus Research |
| 2024-11-18 | Buy | Hold | HSBC |
| 2024-08-06 | Hold | Sell | Deutsche Bank |
| 2024-08-05 | Sector Perform | Outperform | RBC Capital |
Interpretation
The current market evaluation of Moderna's stock suggests that analysts remain cautious, reflecting both the company's innovative potential and the inherent risks in the biotech sector. The shift towards 'Hold' indicates a balanced view, where neither significant upsides nor risks dominate sentiments. However, stability in 'Sell' ratings may signal a degree of underlying uncertainty. Continuous monitoring of rating shifts could provide further clarity on market expectations.
Conclusion
In summary, while Moderna continues to lead in the biotechnology field, analysts exhibit a cautious stance with a tendency towards neutrality. The predominance of 'Hold' ratings reflects a market patiently observing how Moderna navigates market challenges while capitalizing on its innovations. This presents a dual opportunity for strategic entry and a warning of potential volatility. Close attention to analyst sentiment could offer predictive insights into potential future market behavior.